Evidence map›Paper›PMID 34591162›Full record

ArticleAnnals of hematology2022

Long-term outcomes following the addition of granulocyte colony-stimulating factor-combined high-dose cytarabine to total body irradiation and cyclophosphamide conditioning in single-unit cord blood transplantation for myeloid malignancies.

Takaaki Konuma, Jun Ooi, Hitomi Nagayama, Akira Tomonari, Nobuhiro Tsukada, Seiko Kato, Toshiro Kawakita, Masamichi Isobe, Maki Monna-Oiwa, Arinobu Tojo and 2 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 8 institutions in 1 country.

Takaaki KonumaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan. tkonuma@ims.u-tokyo.ac.jp.ORCID http://orcid.org/0000-0002-1496-376X
Jun OoiDepartment of Health and Nutrition, University of Human Arts and Sciences, Saitama, Japan.
Hitomi NagayamaInternational Research Center for Medical Science, Kumamoto University, Kumamoto, Japan.
Akira TomonariDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Nobuhiro TsukadaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Seiko KatoDepartment of Hematology, Yokohama Minami Kyousai Hospital, Kanagawa, Japan.
Toshiro KawakitaDepartment of Hematology, National Hospital Organisation Kumamoto Medical Center, Kumamoto, Japan.
Masamichi IsobeDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Maki Monna-OiwaDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Arinobu TojoDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
Tohru IsekiDepartment of Transfusion Medicine and Cell Therapy, Chiba University Hospital, Chiba, Japan.
Satoshi TakahashiDepartment of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, 4-6-1, Shirokanedai, Minato-ku, Tokyo, 108-8639, Japan.
The University of Tokyo · JPChiba University Hospital · JPEisai (Japan) · JPJapanese Red Cross Medical Center · JPKumamoto Medical Center · JPKumamoto University · JPUniversity of Human Arts and Sciences · JPYokohama Minami Kyosai Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

An intensified myeloablative conditioning regimen, involving the addition of granulocyte colony-stimulating factor (G-CSF)-combined high-dose cytarabine (12 g/m

Indexed as

AdolescentAdultCord Blood Stem Cell TransplantationCyclophosphamideCytarabineFemaleGranulocyte Colony-Stimulating FactorHumansImmunosuppressive AgentsLeukemia, MyeloidMaleMiddle AgedRetrospective StudiesSurvival AnalysisTransplantation ConditioningTreatment OutcomeCyclophosphamideCytarabineGranulocyte Colony-Stimulating FactorImmunosuppressive AgentsAcute myeloid leukemiaConditioning regimenCord blood transplantationGranulocyte colony-stimulating factorMyelodysplastic syndrome

Identifiers

PMID34591162
OpenAlexW3203299596

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.